Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

By M. Gertz, R. Comenzo, R. Falk, J. Fermand, B. Hazenberg, P. Hawkins, G. Merlini, P. Moreau, P. Ronco, V. Sanchorawala and 3 more. American journal of hematology/oncology, 2005

1,380 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3c773519fd396121d800f9fb4d33baee6a40ad3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

S. Rajkumar

In Molecular Biology

Citations in the corpus

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. (2009, background): “The panel shows the protein accession code in the UniProt database,19 the molecular weight of the protein (MW), the results of the blank control sample, and 4 different microdissections (1-4) For each protein identified in each sample, statistical probability is indicated as a percentage.”
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. (2013, methodology): “The categorization into definite or no cardiac involvement was based on international consensus criteria (14).”
Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis (2012, methodology): “A confirmatory diagnosis consisted of either (1) an endomyocardial biopsy consistent with CA,(5) or (2) a positive non-cardiac biopsy for amyloidosis and cardiac magnetic resonance imaging (CMR) with classic features,(6) or (3) a positive non-cardiac biopsy with characteristic non-strain-based echoc”
Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types (2009, neutral): “LV hypertrophy (Sokolow 35 mm), n/N (%) 4/146 (3) 3/59 (5) 1 (6) 0.”
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009, background): “the deeper the FLC response, the higher the likelihood of both organ and hematologic complete response.(35) Moreover, Palladini et al.”